Valosin-Containing Protein (VCP), also known as p97 in mammals or CDC48 in yeast, is a highly conserved AAA+ (ATPase Associated with various cellular Activities) adenosine triphosphatase that plays central roles in protein quality control, ER-associated degradation (ERAD), autophagy, chromatin dynamics, and DNA repair. VCP forms a hexameric ring complex that uses ATP hydrolysis to extract ubiquitinated substrates from membranes or protein complexes, making it essential for cellular homeostasis[1].
Pathogenic mutations in the VCP gene cause a multisystem disorder termed inclusion body myopathy with early-onset Paget disease of bone (PDB) and frontotemporal dementia (IBMPFD), now more broadly termed VCP disease. This condition is characterized by progressive muscle weakness (inclusion body myopathy), bone deformities (Paget disease), and progressive dementia (FTD). Additionally, VCP mutations are found in approximately 1-2% of familial amyotrophic lateral sclerosis (ALS) cases and are implicated in the pathogenesis of sporadic ALS and FTD[2].
VCP is a 97 kDa protein composed of an N-terminal (N) domain followed by two ATPase domains (D1 and D2) and a C-terminal (C) domain:
N-terminal domain (1-200 aa): Contains the N/D1 linker and mediates cofactor binding. The N-domain itself adopts a double-psi beta barrel fold that interacts with various cofactors including UFD1-NPL4, p47, and UBXD proteins.
D1 ATPase domain (200-400 aa): The first ATPase domain responsible for hexamer assembly. This domain forms the core of the ring structure and contributes to ATP-dependent conformational changes.
D2 ATPase domain (400-760 aa): The major ATPase activity resides here, responsible for the bulk of mechanical work performed by VCP. The D2 domain undergoes dramatic conformational changes during the ATP hydrolysis cycle.
C-terminal domain (760-806 aa): Provides regulatory functions and serves as a binding platform for additional interactors.
VCP assembles as a homo-hexamer, forming a barrel-like structure with central pore. Each monomer contributes to the overall complex, and the six ATPase sites coordinate their activities. This architecture allows VCP to translocate substrates through its central channel, using the energy from ATP hydrolysis to "pull" or "extract" proteins from complexes or membranes.
VCP undergoes dramatic ATP-dependent conformational changes:
ATP-bound state (pre-hydrolysis): The D1 and D2 domains adopt a "closed" conformation, with the N-domains positioned to engage substrates.
Transition state (ATP hydrolysis): Sequential ATP hydrolysis around the hexamer triggers wave-like conformational changes.
ADP-bound state (post-hydrolysis): An "open" conformation allows substrate release. The N-domain rotates and lifts, releasing the extracted substrate.
This cycle can be repeated multiple times, allowing VCP to process numerous substrates.
VCP recruits specific cofactors that determine its substrate specificity and cellular function:
| Cofactor | Function | Cellular Role |
|---|---|---|
| UFD1-NPL4 | Substrate recognition | ERAD, extraction from membranes |
| p47 | Membrane fusion | Nuclear envelope reassembly, Golgi reformation |
| UBXD1/UBXD8 | Ubiquitin chain binding | ERAD, sterol regulation |
| Ataxin-3 | Deubiquitination | Processing of K48-linked chains |
| p37 | Membrane trafficking | ER-Golgi transport |
The pathogenic mutations in VCP predominantly affect cofactor binding, particularly to UFD1-NPL4, disrupting the protein's normal function in substrate extraction.
VCP is central to cellular protein quality control systems:
ER-Associated Degradation (ERAD): VCP, in complex with UFD1-NPL4, extracts misfolded proteins from the endoplasmic reticulum lumen or membrane for delivery to the proteasome. This process is essential for maintaining ER homeostasis and preventing accumulation of toxic protein aggregates[1:1].
Ubiquitin-Proteasome System: VCP delivers polyubiquitinated substrates to the 26S proteasome, functioning as a "segregase" that separates substrates from their binding partners before proteasomal degradation.
Mitochondrial Quality Control: VCP participates in mitochondrial protein turnover, extracting damaged proteins from the mitochondrial outer membrane for degradation.
VCP plays multiple roles in autophagy:
Autophagosome Maturation: VCP is required for autophagosome-lysosome fusion. Loss of VCP function leads to accumulation of immature autophagic vacuoles.
Selective Autophagy: VCP participates in selective autophagy pathways, including the clearance of protein aggregates (aggrephagy) and damaged organelles (mitophagy, ribophagy).
Stress Granule Dynamics: VCP regulates stress granule assembly and disassembly. Mutations in VCP cause abnormal stress granule persistence, leading to toxic RNA granule accumulation[3].
VCP participates in several DNA repair pathways[4]:
VCP mutations cause a spectrum of disorders:
Inclusion Body Myopathy (IBM): Progressive muscle weakness beginning in adulthood, typically in the third or fourth decade. Muscle pathology shows rimmed vacuoles containing phosphorylated TDP-43.
Paget Disease of Bone (PDB): Increased bone turnover with characteristic lytic and sclerotic lesions, primarily affecting spine, pelvis, and long bones.
Frontotemporal Dementia (FTD): Progressive decline in executive function, behavior, and language. Neuropathology shows frontotemporal atrophy with TDP-43 inclusions.
Amyotrophic Lateral Sclerosis (ALS): Progressive motor neuron degeneration with muscle weakness, atrophy, and fasciculations. VCP-related ALS shares features with other genetic forms.
Over 50 pathogenic VCP mutations have been identified, predominantly in the N-domain:
| Mutation | Location | Phenotype | Frequency |
|---|---|---|---|
| R155H/C | N-domain | IBM/FTD/ALS | Most common |
| R191Q | N-domain | IBM/FTD | Common |
| A232E | N-domain | Severe IBM/ALS | Severe |
| G97E | N-domain | FTD | Less common |
| P137L | N-domain | IBM | Rare |
These mutations cause disease through a combination of:
A hallmark of VCP disease is TDP-43 proteinopathy. Pathological TDP-43 inclusions are found in:
VCP mutations alter TDP-43 dynamics through impaired autophagy and altered stress granule processing, leading to cytoplasmic accumulation and phosphorylation of TDP-43[5].
Different mutations show variable penetrance and phenotype expression:
VCP Inhibitors: Specific inhibitors that reduce toxic gain-of-function are being developed. However, complete inhibition is toxic, necessitating careful dosing[6].
Autophagy Enhancers: Compounds that compensate for impaired autophagic clearance:
Protein Aggregation Inhibitors: Agents that prevent TDP-43 and other protein aggregation.
Antisense Oligonucleotides (ASOs): Targeting mutant VCP transcripts for degradation. ASOs can selectively reduce mutant protein while preserving wild-type expression.
Gene Replacement: AAV-delivered wild-type VCP. Currently in preclinical development.
CRISPR Editing: Potential for directly correcting pathogenic mutations. Challenges include delivery to muscle and CNS.
Multidisciplinary care includes:
Currently no approved disease-modifying therapies for VCP disease. Clinical trials for related disorders (ALS, FTD) may inform therapeutic development for VCP-associated disease.
Zhao M, et al. ERAD and VCP: implications for neurodegenerative diseases. Nature Reviews Neuroscience. 2020. ↩︎ ↩︎
Ji YJ, et al. VCP mutations in ALS and FTD: mechanisms and therapeutic targeting. Acta Neuropathologica. 2021. ↩︎
Buchan JR, et al. p97/VCP drives liquid phase separation and aggregation of stress granules. Cell. 2013. ↩︎
Kopp F, et al. VCP in DNA repair: role in genome stability. DNA Repair. 2019. ↩︎
Kim HJ, et al. VCP mutations alter TDP-43 dynamics and cause ALS/FTD. Neuron. 2013. ↩︎
Davidson GS, et al. VCP inhibitors as therapeutic agents in ALS/FTD. Neurobiology of Disease. 2020. ↩︎